Header Logo

Connection

Michael Brehm to Transplantation, Heterologous

This is a "connection" page, showing publications Michael Brehm has written about Transplantation, Heterologous.
Connection Strength

1.530
  1. Yao LC, Aryee KE, Cheng M, Kaur P, Keck JG, Brehm MA. Creation of PDX-Bearing Humanized Mice to Study Immuno-oncology. Methods Mol Biol. 2019; 1953:241-252.
    View in: PubMed
    Score: 0.597
  2. Brehm MA, Bortell R, Diiorio P, Leif J, Laning J, Cuthbert A, Yang C, Herlihy M, Burzenski L, Gott B, Foreman O, Powers AC, Greiner DL, Shultz LD. Human immune system development and rejection of human islet allografts in spontaneously diabetic NOD-Rag1null IL2rgammanull Ins2Akita mice. Diabetes. 2010 Sep; 59(9):2265-70.
    View in: PubMed
    Score: 0.331
  3. Shultz LD, Keck J, Burzenski L, Jangalwe S, Vaidya S, Greiner DL, Brehm MA. Humanized mouse models of immunological diseases and precision medicine. Mamm Genome. 2019 06; 30(5-6):123-142.
    View in: PubMed
    Score: 0.151
  4. Ali R, Babad J, Follenzi A, Gebe JA, Brehm MA, Nepom GT, Shultz LD, Greiner DL, DiLorenzo TP. Genetically modified human CD4(+) T cells can be evaluated in?vivo without lethal graft-versus-host disease. Immunology. 2016 08; 148(4):339-51.
    View in: PubMed
    Score: 0.126
  5. Brehm MA, Powers AC, Shultz LD, Greiner DL. Advancing animal models of human type 1 diabetes by engraftment of functional human tissues in immunodeficient mice. Cold Spring Harb Perspect Med. 2012 May; 2(5):a007757.
    View in: PubMed
    Score: 0.094
  6. Covassin L, Laning J, Abdi R, Langevin DL, Phillips NE, Shultz LD, Brehm MA. Human peripheral blood CD4 T cell-engrafted non-obese diabetic-scid IL2r?(null) H2-Ab1 (tm1Gru) Tg (human leucocyte antigen D-related 4) mice: a mouse model of human allogeneic graft-versus-host disease. Clin Exp Immunol. 2011 Nov; 166(2):269-80.
    View in: PubMed
    Score: 0.091
  7. Borel F, Tang Q, Gernoux G, Greer C, Wang Z, Barzel A, Kay MA, Shultz LD, Greiner DL, Flotte TR, Brehm MA, Mueller C. Survival Advantage of Both Human Hepatocyte Xenografts and Genome-Edited Hepatocytes for Treatment of a-1 Antitrypsin Deficiency. Mol Ther. 2017 11 01; 25(11):2477-2489.
    View in: PubMed
    Score: 0.034
  8. Greiner DL, Brehm MA, Hosur V, Harlan DM, Powers AC, Shultz LD. Humanized mice for the study of type 1 and type 2 diabetes. Ann N Y Acad Sci. 2011 Dec; 1245:55-8.
    View in: PubMed
    Score: 0.023
  9. Diiorio P, Jurczyk A, Yang C, Racki WJ, Brehm MA, Atkinson MA, Powers AC, Shultz LD, Greiner DL, Bortell R. Hyperglycemia-induced proliferation of adult human beta cells engrafted into spontaneously diabetic immunodeficient NOD-Rag1null IL2r?null Ins2Akita mice. Pancreas. 2011 Oct; 40(7):1147-9.
    View in: PubMed
    Score: 0.023
  10. Racki WJ, Covassin L, Brehm M, Pino S, Ignotz R, Dunn R, Laning J, Graves SK, Rossini AA, Shultz LD, Greiner DL. NOD-scid IL2rgamma(null) mouse model of human skin transplantation and allograft rejection. Transplantation. 2010 Mar 15; 89(5):527-36.
    View in: PubMed
    Score: 0.020
  11. Pino S, Brehm MA, Covassin-Barberis L, King M, Gott B, Chase TH, Wagner J, Burzenski L, Foreman O, Greiner DL, Shultz LD. Development of novel major histocompatibility complex class I and class II-deficient NOD-SCID IL2R gamma chain knockout mice for modeling human xenogeneic graft-versus-host disease. Methods Mol Biol. 2010; 602:105-17.
    View in: PubMed
    Score: 0.020
  12. King MA, Covassin L, Brehm MA, Racki W, Pearson T, Leif J, Laning J, Fodor W, Foreman O, Burzenski L, Chase TH, Gott B, Rossini AA, Bortell R, Shultz LD, Greiner DL. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol. 2009 Jul; 157(1):104-18.
    View in: PubMed
    Score: 0.019
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.